SLC9A6, solute carrier family 9 member A6, 10479

N. diseases: 210; N. variants: 15
Disease: Cystic Fibrosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE These results suggest that tedizolid represents a promising therapeutic option for the treatment of CF-associated MRSA/MSSA infections, having potent in vivo activity and low resistance potential. 31617901 2020
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE Duplicate isolates from the same site and year and those obtained for MRSA surveillance or from patients with cystic fibrosis were excluded. 30753206 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE MRSA and Trichosporon) along with B. contaminans ST102 might have contributed to the worsening of clinical conditions in our CF patients. 31464603 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE MRSA is also the first group of pathogens that infect the pulmonary tract in young patients with cystic fibrosis. 30215733 2018
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE This case report describes the successful use of continuous vancomycin, including improvement in lung function and avoidance of nephrotoxicity, demonstrated in a pediatric cystic fibrosis (CF) patient with MRSA. 29193836 2018
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE In the United States, prevalence of MRSA in CF is around 27%, but is much lower (3-18%) in most other countries. 30073802 2018
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE Fine particulate matter is an independent risk factor for initial MRSA acquisition in young children with CF. 28750627 2017
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE The aim of this multicentre study was to analyse MRSA strains isolated from CF patients attending nine Italian CF care centres during a two-year period (2004-2005). 21752729 2011
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE All 57 MRSA from CF patients harbored the multiresistant cassette type III. 20802934 2011
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 GeneticVariation disease BEFREE When compared with the total adult CF population, the older patients were significantly less likely to have a DeltaF508 mutation or colonisation with Stenotrophomonas maltophilia and MRSA; but more likely to have pancreatic sufficiency, colonisation with Pseudomonas aeruginosa or allergic bronchopulmonary aspergillosis. 19022643 2009
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.100 Biomarker disease BEFREE Analysis of CF-Marseille shows a similar core genome to that of previously sequenced MRSA strains but with a different genomic organization due to the presence of specific mobile genetic elements i.e. a new SCCmec type IV mosaic cassette that has integrated the pUB110 plasmid, and a new phage closely related to phiETA3. 19144117 2009